VPVirginia A. Pedicord

Virginia A. Pedicord

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Virginia A. Pedicord has a total of 95 co-authors. Here are the top co-authors by number of shared publications:

  • Amelia T. Soderholm

    Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, UK

    6 shared publications
  • Benjamin S. Beresford-Jones

    Jeffrey Cheah Biomedical Centre, Cambridge Institute of Therapeutic Immunology and Infectious Disease, Cambridge Biomedical Campus, Cambridge, UK

    4 shared publications
  • Katherine Harcourt

    Jeffrey Cheah Biomedical Centre, Cambridge Institute of Therapeutic Immunology and Infectious Disease, Cambridge Biomedical Campus, Cambridge, UK

    4 shared publications
  • Satoshi Suyama

    Jeffrey Cheah Biomedical Centre, Cambridge Institute of Therapeutic Immunology and Infectious Disease, Cambridge Biomedical Campus, Cambridge, UK

    4 shared publications
  • Simon Clare

    Jeffrey Cheah Biomedical Centre, Cambridge Institute of Therapeutic Immunology and Infectious Disease, Cambridge Biomedical Campus, Cambridge, UK

    4 shared publications
  • Benjamin S. Beresford-Jones

    Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge

    3 shared publications

Latest Publications

  • Open Access

    The Role of the Microbiome in the Resolution of Infection-Induced Inflammation

    by Kerry McGowen, Junhee Lee, Virginia A. Pedicord

    The host microbiome plays a crucial protective role against pathogenic infections, not only through direct competition with invading pathogens but also by coordinating host antimicrobial and barrier functions and educating immune cells. While essential for pathogen clearance, unchecked, prolonged, or excessive inflammation from host immune responses can paradoxically lead to serious consequences for the host including the development of chronic inflammatory and autoimmune diseases. Recent research highlights how microbiome disruptions can exacerbate infection-associated inflammation and pathology. Even with established links among microbes, inflammation, and infection susceptibility, a comprehensive understanding of the cellular and molecular mechanisms connecting the microbiome's role in resolving infection-associated inflammation remains largely undefined. This review discusses our current understanding of the microbiome's contribution to resolving inflammation and tissue damage postinfection and its potential impact on therapeutic approaches for alleviating infection-induced inflammatory diseases.


  • Open Access

    Enterocloster clostridioformis protects against Salmonella pathogenesis and modulates epithelial and mucosal immune function

    by Benjamin S. Beresford-Jones, Satoshi Suyama, Simon Clare, Amelia Soderholm, Wangmingyu Xia, Puspendu Sardar, Junhee Lee, Katherine Harcourt, Trevor D. Lawley, Virginia A. Pedicord

    Background: Promoting resistance to enteric pathogen infection is a core function of the gut microbiota; however, many of the specific host–commensal interactions that mediate this protection remain uncharacterised. To address this knowledge gap, we monocolonised germ-free mice with mouse-derived commensal microbes to screen for microbiota-induced resistance to Salmonella Typhimurium infection. Results: We identified Enterocloster clostridioformis as a protective species against S. Typhimurium infection. E. clostridioformis selectively upregulates resistin-like molecule β and cell cycle pathway expression at the level of caecal epithelial cells and increases T-regulatory cells in the underlying mucosal immune system, potentially contributing to reduced infection-induced pathology. Conclusions: We highlight novel mechanisms of host–microbe interactions that can mediate microbiota-induced resistance to acute salmonellosis. In the backdrop of increasing antibiotic resistance, this study identifies novel potential avenues for further research into protective host responses against enteric infections and could lead to new therapeutic approaches.


  • Open Access

    Gut microbiota-derived hexa-acylated lipopolysaccharides enhance cancer immunotherapy responses

    by Puspendu Sardar, Benjamin S. Beresford-Jones, Wangmingyu Xia, Omar Shabana, Satoshi Suyama, Ruben J. F. Ramos, Amelia T. Soderholm, Panagiotis Tourlomousis, Paula Kuo, Alexander C. Evans, et al.

    The gut microbiome modulates immunotherapy treatment responses, and this may explain why immune checkpoint inhibitors, such as anti-PD-1, are only effective in some patients. Previous studies correlated lipopolysaccharide (LPS)-producing gut microbes with poorer prognosis; however, LPS from diverse bacterial species can range from immunostimulatory to inhibitory. Here, by functionally analysing faecal metagenomes from 112 patients with melanoma, we found that a subset of LPS-producing bacteria encoding immunostimulatory hexa-acylated LPS was enriched in microbiomes of clinical responders. In an implanted tumour mouse model of anti-PD-1 treatment, microbiota-derived hexa-acylated LPS was required for effective anti-tumour immune responses, and LPS-binding antibiotics and a small-molecule TLR4 antagonist abolished anti-PD-1 efficacy. Conversely, oral administration of hexa-acylated LPS to mice significantly augmented anti-PD-1-mediated anti-tumour immunity. Penta-acylated LPS did not improve anti-PD-1 efficacy in vivo and inhibited hexa-acylated LPS-induced immune activation in vitro. Microbiome hexa-acylated LPS therefore represents an accessible predictor and potential enhancer of immunotherapy responses.


  • Open Access

    Hexa-acylated lipopolysaccharides from the gut microbiota enhance cancer immunotherapy responses

    by Benjamin S. Beresford-Jones, Puspendu Sardar, Wangmingyu Xia, Omar Shabana, Satoshi Suyama, Ruben J. Jesus Faustino Ramos, Amelia T. Soderholm, Panagiotis Tourlomousis, Paula Kuo, Alexander C. Evans, et al.

    Immune checkpoint inhibitors (ICI), such as anti-PD-1, have revolutionized cancer treatment, but they are only effective for a minority of patients. The gut microbiome plays a crucial role in modulating immunotherapy treatment responses, and previous studies correlated lipopolysaccharide (LPS)-producing gut microbes with poorer prognosis. However, LPS from diverse bacterial species have activities ranging from immunostimulatory to inhibitory. By functionally analyzing fecal metagenomes from 112 melanoma patients prior to anti-PD-1 therapy, we found that a subset of LPS-producing bacteria encoding immunostimulatory hexa-acylated LPS was enriched in the microbiomes of clinical responders. We confirmed robust activation of the NF-kB pathway by hexa-acylated LPS in vitro , and this activation was significantly inhibited by penta-acylated LPS in a dose-dependent manner. Importantly, oral administration of hexa-acylated LPS augmented anti-PD-1-mediated anti-tumor immunity in an in vivo mouse model of cancer immunotherapy. Microbiome hexa-acylated LPS may therefore represent an accessible predictor and potential enhancer of clinical anti- PD-1 immunotherapy responses. Statement of significance: Functional rather than taxonomic profiling of patient gut microbiomes reveals hexa-acylated LPS as a novel biomarker of responsiveness and a targetable pathway for enhancing responses to anti-PD-1, informing future studies and current patient treatment.

  • Open Access

    The microbial composition of pancreatic ductal adenocarcinoma: a systematic review of 16S rRNA gene sequencing

    by Nabeel Merali, Tarak Chouari, Casie Sweeney, James Halle-Smith, Maria-Danae Jessel, Bing Wang, James O’ Brien, Satoshi Suyama, José I. Jiménez, Keith J. Roberts, et al.

    Background: Pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDAC), continues to pose a significant clinical and scientific challenge. The most significant finding of recent years is that PDAC tumours harbour their specific microbiome, which differs amongst tumour entities and is distinct from healthy tissue. This review aims to evaluate and summarise all PDAC studies that have used the next-generation technique, 16S rRNA gene amplicon sequencing within each bodily compartment. As well as establishing a causal relationship between PDAC and the microbiome. Materials and methods: This systematic review was carried out according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. A comprehensive search strategy was designed, and 1727 studies were analysed. Results: In total, 38 studies were selected for qualitative analysis and summarised significant PDAC bacterial signatures. Despite the growing amount of data provided, we are not able to state a universal 16S rRNA gene microbial signature that can be used for PDAC screening. This is most certainly due to the heterogeneity of the presentation of results, lack of available datasets, and the intrinsic selection bias between studies. Conclusion: Several key studies have begun to shed light on causality and the influence the microbiome constituents and their produced metabolites could play in tumorigenesis and influencing outcomes. The challenge in this field is to shape the available microbial data into targetable signatures. Making sequenced data readily available is critical, coupled with the coordinated standardisation of data and the need for consensus guidelines in studies investigating the microbiome in PDAC.


  • Open Access

    Enterocloster clostridioformis induces host intestinal epithelial responses that protect against Salmonella infection

    by Benjamin S. Beresford-Jones, Satoshi Suyama, Simon Clare, Amelia T Soderholm, Wangmingyu Xia, Puspendu Sardar, Katherine Harcourt, Trevor D. Lawley, Virginia A. Pedicord

    Promoting resistance to enteric pathogen infection is a core function of the gut microbiota. However, many of the host-commensal interactions that likely mediate this protection remain uncharacterised. By screening gnotobiotic mice monocolonised with a range of mouse-derived commensal bacteria we have identified Enterocloster clostridioformis as a protective species against Salmonella Typhimurium infection. Unlike the colonisation resistance induced by some commensal bacteria, E. clostridioformis selectively induces a previously uncharacterised microbe adaptation response at the level of the caecal intestinal epithelium and the underlying mucosal immune system to mediate host-dependent resistance to infection. Triggering this pathway may therefore constitute a novel strategy to enhance protective responses against enteric infections.


  • Open Access

    Identification of gut microbial species linked with disease variability in a widely used mouse model of colitis

    by Samuel C. Forster, Simon Clare, Benjamin S. Beresford-Jones, Katherine Harcourt, George Notley, Mark D. Stares, Nitin Kumar, Amelia T. Soderholm, Anne Adoum, Hannah Wong, et al.

    Experimental mouse models are central to basic biomedical research; however, variability exists across genetically identical mice and mouse facilities making comparisons difficult. Whether specific indigenous gut bacteria drive immunophenotypic variability in mouse models of human disease remains poorly understood. We performed a large-scale experiment using 579 genetically identical laboratory mice from a single animal facility, designed to identify the causes of disease variability in the widely used dextran sulphate sodium mouse model of inflammatory bowel disease. Commonly used treatment endpoint measures—weight loss and intestinal pathology—showed limited correlation and varied across mouse lineages. Analysis of the gut microbiome, coupled with machine learning and targeted anaerobic culturing, identified and isolated two previously undescribed species, Duncaniella muricolitica and Alistipes okayasuensis, and demonstrated that they exert dominant effects in the dextran sulphate sodium model leading to variable treatment endpoint measures. We show that the identified gut microbial species are common, but not ubiquitous, in mouse facilities around the world, and suggest that researchers monitor for these species to provide experimental design opportunities for improved mouse models of human intestinal diseases.


  • Top Cited Papers
    Open Access

    The Mouse Gastrointestinal Bacteria Catalogue enables translation between the mouse and human gut microbiotas via functional mapping

    by Benjamin S. Beresford-Jones, Samuel C. Forster, Mark D. Stares, George Notley, Elisa Viciani, Hilary P. Browne, Daniel J. Boehmler, Amelia T. Soderholm, Nitin Kumar, Kevin Vervier, et al.


  • Open Access

    Novel gut pathobionts confound results in a widely used mouse model of human inflammatory disease

    by Samuel C. Forster, Simon Clare, Benjamin S. Beresford-Jones, Katherine Harcourt, George Notley, Mark Stares, Nitin Kumar, Amelia T. Soderholm, Anne Adoum, Hannah Wong, et al.

    The mammalian gut microbiota consists of hundreds of anaerobic bacterial species that shape intestinal homeostasis and influence host immune responses. Although the causal roles of specific human gut bacterial species in health and disease are emerging, the role of indigenous gut bacteria in driving immunophenotypic variability in mouse models of human disease remains poorly understood. We performed a large-scale experiment using 579 laboratory mice designed to identify and validate the causes of disease variability in the widely used dextran sulphate sodium (DSS) mouse model of inflammatory bowel disease. Using microbiome analysis, coupled with machine learning and targeted anaerobic culturing, we identified and isolated the novel gut pathobiont species Duncaniella muricolitica and Alistipes okayasuensis and fulfilled Koch’s postulates in mice to show that each pathobiont exerts dominant effects in the DSS model leading to variable treatment responses. We show these pathobiont species are common, but not ubiquitous, in mouse facilities around the world, raising experimental design opportunities for improved mouse models of human intestinal diseases.


  • Open Access

    Intestinal epithelial cells: at the interface of the microbiota and mucosal immunity

    by Amelia T. Soderholm, Virginia A. Pedicord

    Summary: The intestinal epithelium forms a barrier between the microbiota and the rest of the body. In addition, beyond acting as a physical barrier, the function of intestinal epithelial cells (IECs) in sensing and responding to microbial signals is increasingly appreciated and likely has numerous implications for the vast network of immune cells within and below the intestinal epithelium. IECs also respond to factors produced by immune cells, and these can regulate IEC barrier function, proliferation and differentiation, as well as influence the composition of the microbiota. The mechanisms involved in IEC–microbe–immune interactions, however, are not fully characterized. In this review, we explore the ability of IECs to direct intestinal homeostasis by orchestrating communication between intestinal microbes and mucosal innate and adaptive immune cells during physiological and inflammatory conditions. We focus primarily on the most recent findings and call attention to the numerous remaining unknowns regarding the complex crosstalk between IECs, the microbiota and intestinal immune cells.